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As reminded by D. Hilton-Jones in this issue’s review [1], the classification of myositides is
currently changing. Since 1975, when Peter and Bohan [2] defined the diagnostic criteria for
polymyositis (PM) and dermatomyositis (DM), the development of new pathological tools [3,4]
permitted to refine the diagnosis criteria, but also, together with fundamental research in
immunology [5] and neurosciences [4] to approach the various physiopathological events leading
to the different acquired inflammatory and/or autoimmune myopathies. Beside the now
‘‘classical and well recognized’’ PM and DM, new insights have been done for the recognition
of inclusion body myositis (IBM) [4] that must be distinguished from PM, but also, for the
recognition of immune-mediated necrotizing myopathies (IMNM) [5] that clearly differ from
inherited myopathies or dystrophies [6]. Among IMNM, some are related to the presence of
particular specific auto-antibodies (anti-SRP), others are associated with neoplasia and the
remaining are also recognized [7] for their property to be treatable by immunosuppressants. The
recent discovery of a new auto-antibody specifically associated to IMNM (neither paraneoplastic,
nor anti-SRP positive) [8] highlights the potential toxic trigger role of statins in the genesis of
IMNM/myositis, since the presence of this antibody was frequently associated with statin
exposure [8]. A few weeks later, the same team also discovered and published the target of
this antibody, which is the 3-hydroxy-3-methylglutaryl-coenzyme A reductase (HMGCR) [9], the
key enzyme in the cholesterol biosynthetic pathway specifically inhibited by statins. They also
showed that statins up-regulate the expression of HMGCR on regenerative muscle fibers [9]
(HMGCR being the major target of autoantibodies in statin-associated IMNM). Undoubtedly,
commercial kits for the routine dosage of this auto-antibody will soon be available, facilitating the
diagnosis of this condition. We will then see if all the myopathies due to the statins are due to the
presence of this antibody.
In the same vein, during the past few years, the burden of the dosages of the different myositis-
specific (or associated) auto-antibodies has increased, an important step forward, since it may
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Within a very short time, we have now a routine access to the
dosage of different antisynthetase antibodies anti-J0-1 (histi-
dyl-tRNA synthetase), PL-7 (threonyl-tRNA synthetase), PL-12
(alanine-tRNA synthetase), OJ (isoleucil-tRNA synthetase), EJ
(glycyl-tRNA synthetase), but also of anti-SRP, Mi-2, Ku, PM-Scl,
RNP antibodies. Furthermore, each year brings the discovery of
new antibodies, not only new anti-synthetases [KS (asparagi-
nyl-tRNA synthetase), ZO (phenylalanyl-tRNA synthetase),
thyrosyl-tRNA synthetase], but also other antibodies, notably
in DM, which have remarkable particularities for the clinician,
such as to be frequently associated with cancer [10,11] or with
rapidly progressive interstitial lung disease [12]. Here again,
the target antigens have been recently precised (respectively
TIF1-g and MDA5) [13], ELISA have been developed, leading to
think that routine test will soon be available.
All these efforts for the development of immunological or
pathological tools and finally for a better classification of the
myositides are aimed to define homogeneous groups of
patients, receiving appropriate treatments. It is now accepted
that conventional immunosuppressants (corticosteroids, metho-
trexate, azathioprine, intravenous immunoglobulins. . .) have no
(or transient andmodest) effects onmuscle strength during IBM.
It is then extremely important to distinguish this condition from
PM, to avoid useless (and potentially dangerous) treatments.
Nevertheless, the debate is still open concerning the primum
movens of IBM: is it an immunological [5] or a degenerative [4]phenomenon? The development of future therapeutic strategies
(and trials) will thus depend of the investigator’s convictions:
unconventional immunosuppressant and/or modulator (such as
certain biotherapies) in one hand or anti-amyloid (such as in
Alzheimer disease) on the other. Nonetheless, for the othermore
easily treatable myositides, one may be surprised, in 2011, by
the weakness of evidence-based medicine [14] and the lack of
recommendations. It is also surprising that inmost of the studies,
PM, DM, overlap syndrome with muscle inflammation or IMNM
are indistinguishably treated in the same manner [14], despite
their different physiopathogenesis. This is presumably due to the
rarity of these diseases, and the lack of worldwide, concerted
effort to date.
However, things are undisputedly changing, as preclinical
models are now mature [3], that will help for the choice of
the molecules to be tested. Efforts are made to set up and
standardize diagnostic criteria and to define outcomes for the
future clinical trials, not only in PM/DM/IMNM [7] but also in
IBM [15,16] and other international workshops are planned.
Furthermore, big pharmaceutical companies are developing
biotherapies potentially targeted for myositides and their
interest for these diseases seems to progress. We can thus
be quite enthusiastic: no doubt that all these efforts will allow,
in the near future, to start multicentric, prospective, rando-
mised trials for the benefit of the patients.References
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